Research article · 27 Feb 2026
Conference abstractPublished 2019
Peripheral protein biomarkers for Parkinson’s disease and synucleinopathies
Case Western Reserve University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Synucleinopathies such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB) are characterized by the deposition of misfolded protein aggregates consisted of alpha-synuclein in the central nervous system (CNS). Previous efforts have focused on the development of CNS-proximal clinical biomarkers, including cerebrospinal fluid measures of alpha-synuclein, and tau. However, these diagnostic techniques are often used in clinical studies on patients with advanced disease state, and are invasive. Therefore, there remains an urgent need for reliable, inexpensive and minimally invasive peripheral biomarkers. Recent studies have revealed widespread peripheral involvement of Lewy bodylike pathology, often prior to clinical manifestations of the diseases. Indeed, alpha-synuclein deposits have been observed in peripheral tissues in PD and DLB. A formidable challenge is that the levels of the amyloidogenic protein aggregates in peripheral tissues are extremely low and thus only variably detectable using immunological methods. Therefore, highly sensitive analytical platforms are required as the new generation of biomarker assays specific for protein aggregates and amyloid fibrils. The real-time quaking induced conversion (RT-QuIC) has emerged as a robust, rapid and ultrasensitive technology for template-assisted amplification of misfolded protein aggregates in neurodegenerative diseases. Using the RT-QuIC technique, our recent studies have shown that disease-associated protein aggregates are readily detectable in peripheral tissues of patients affected by PD, and dementia with Lewy bodies. Validation of peripheral protein biomarkers will enable sensitive premortem diagnostic tests for PD, DLB, and other related disorders, and accelerate clinical trials for disease-modifying therapies.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neuroscience & Clinical Research.
Commentary · 28 Jun 2024
Cellular Responses in Neural Pathology: Neurons, Neuroglia and Connective Tissues
Short communication · 28 Jun 2024
Brain Health Across the Lifespan: Strategies for Cognitive Vitality
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neuroscience & Clinical Research
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Shu G Chen”
